Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause.
Expert Rev Clin Pharmacol
; 15(2): 121-137, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-35306927
ABSTRACT
INTRODUCTION:
Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile. AREAS COVERED This narrative review discusses E4's pharmacological characteristics, mode of action, and the results of preclinical and clinical studies for contraception, as well as for menopause and oncology. EXPERT OPINION Extensive studies have elucidated the properties of E4 that underlie its favorable safety profile. While classical estrogens (such as estradiol) exert their actions via both activation of nuclear and membrane estrogen receptor α (ERα), E4 presents a specific profile of ERα activation E4 binds and activates nuclear ERα but does not induce the activation of membrane ERα signaling pathways in specific tissues. E4 has a small effect on normal breast tissue proliferation and minimally affects hepatic parameters. This distinct profile of ERα activation, uncoupling nuclear and membrane activation, is unique.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Estetrol
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Expert Rev Clin Pharmacol
Year:
2022
Document type:
Article
Affiliation country:
Belgium